Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.

Wolffenbuttel BHR, Brugts MP, Catarig AM, Clark A, Kok M, Lieverse AG, van Soest J

Advances in therapy21 Dec 2022Cited by 19 (Europe PMC)

PMID36542260PMCIDPMC9768392DOI10.1007/s12325-022-02385-xPepBankPUB-36542260

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, once-weekly semaglutide reduced mean HbA1c by 1.2 %-points from baseline at about 30 weeks.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide lowered HbA1c by 1.2 percentage points from baseline.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n = 186
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2 %-points
end of study
Source sentences
Summary
In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbA_1c with semaglutide was - 1.2%-points (95% [confidence interval] CI - 1.3; - 1.0; p 1c targets of < 8.0%, < 7.5% a…
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226001
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, semaglutide reduced mean body weight by 7.8 kg from baseline.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide lowered body weight by 7.8 kg from baseline.
Peptide
Semaglutide
Outcome
DecreaseBody weight change (kg)
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Body weight change
−7.8 kg
end of study
Source sentences
Summary
Mean reduction in BW was - 7.8 kg [95% CI - 8.7; - 6.8; p < 0.0001], corresponding to relative reduction of - 7.5% [95% CI - 8.4; - 6.6; p < 0.0001].
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226005
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, semaglutide reduced body weight by 7.5% relative to baseline.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide lowered body weight by 7.5% from baseline.
Peptide
Semaglutide
Outcome
DecreaseBody weight change (relative)
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Relative body weight change
−7.5%
end of study
Source sentences
Summary
Mean reduction in BW was - 7.8 kg [95% CI - 8.7; - 6.8; p < 0.0001], corresponding to relative reduction of - 7.5% [95% CI - 8.4; - 6.6; p < 0.0001].
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226006
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, semaglutide reduced waist circumference by 8.8 cm from baseline.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide cut waist size by 8.8 cm from baseline.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference change
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Waist circumference change
−8.8 cm
end of study
Source sentences
Summary
Improvements in WC (- 8.8 cm [95% CI - 10.4; - 7.2; p < 0.0001])
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226007
05HumanObservational studySafety outcome
In adults with type 2 diabetes in routine care, one serious adverse drug reaction (cholecystitis) was reported with semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, one serious side effect (gallbladder inflammation) was reported on semaglutide.
Peptide
Semaglutide
Outcome
Not applicableSerious adverse drug reaction
Study
n = 211
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Serious adverse drug reactions
1 participants
cholecystitis
Source sentences
Summary
One serious adverse drug reaction (cholecystitis) was reported.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226010
06HumanObservational studySafety outcome
In adults with type 2 diabetes in routine care, eight participants, all on concomitant insulin, had severe or documented hypoglycaemia on semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, eight people, all also using insulin, had low blood sugar episodes on semaglutide.
Peptide
Semaglutide
Outcome
Not applicableSevere or documented hypoglycaemia
Study
n = 211
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Participants with hypoglycaemia
8 participants
all on concomitant insulin
Source sentences
Summary
Eight participants (all receiving concomitant insulin) experienced severe or documented hypoglycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226011
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 70.5% of participants on semaglutide reached HbA1c below 8.0%.
In plain wordsIn adults with type 2 diabetes in routine care, 70.5% reached HbA1c below 8.0% on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseHbA1c below 8.0% at end of study
Study
n = 186
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Responders HbA1c <8.0%
70.5%
end of study
Source sentences
Summary
In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbA_1c with semaglutide was - 1.2%-points (95% [confidence interval] CI - 1.3; - 1.0; p 1c targets of < 8.0%, < 7.5% a…
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226002
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 54.0% of participants on semaglutide reached HbA1c below 7.5%.
In plain wordsIn adults with type 2 diabetes in routine care, 54.0% reached HbA1c below 7.5% on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseHbA1c below 7.5% at end of study
Study
n = 186
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Responders HbA1c <7.5%
54%
end of study
Source sentences
Summary
In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbA_1c with semaglutide was - 1.2%-points (95% [confidence interval] CI - 1.3; - 1.0; p 1c targets of < 8.0%, < 7.5% a…
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226003
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 36.9% of participants on semaglutide reached HbA1c below 7.0%.
In plain wordsIn adults with type 2 diabetes in routine care, 36.9% reached HbA1c below 7.0% on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseHbA1c below 7.0% at end of study
Study
n = 186
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Measurements
Responders HbA1c <7.0%
36.9%
end of study
Source sentences
Summary
In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbA_1c with semaglutide was - 1.2%-points (95% [confidence interval] CI - 1.3; - 1.0; p 1c targets of < 8.0%, < 7.5% a…
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226004
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, health-related quality of life improved from baseline on semaglutide, including across most SF-36 domains.
In plain wordsIn adults with type 2 diabetes in routine care, quality of life improved from baseline on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseHealth-related quality of life
Study
n: not reported in source
Comparator
Baseline
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Source sentences
Summary
Improvements in WC (- 8.8 cm [95% CI - 10.4; - 7.2; p < 0.0001]), HRQoL and treatment satisfaction were observed, including across most Short-Form 36 Health Survey domains.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226008
11HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, treatment satisfaction improved from baseline on semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, satisfaction with treatment improved from baseline on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseTreatment satisfaction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated · approx. 30 weeksAs given in this study (human).
Source sentences
Summary
Improvements in WC (- 8.8 cm [95% CI - 10.4; - 7.2; p < 0.0001]), HRQoL and treatment satisfaction were observed, including across most Short-Form 36 Health Survey domains.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study.
Summary · context
In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA.
Report a problemFND-3654226009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT03929679

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Novo Nordisk A/Sn = 21828 May 2019 to 24 Nov 2020

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 20 Jan 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.